Key features of extrauterine pelvic serous tumours (fallopian tube, ovary, and peritoneum)

Histopathology

Volumn 61, Issue 3, 2012, Pages 329-339

  Delair, Deborah ^a   Soslow, Robert A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

BRCA1 and 2; High grade serous carcinoma; Low grade serous carcinoma; Ovarian cancer; Precursor lesions; Serous borderline tumour

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; B RAF KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; ESTROGEN RECEPTOR; K RAS PROTEIN; KI 67 ANTIGEN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN P53; TAXANE DERIVATIVE; TRANSCRIPTION FACTOR PAX8;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CARCINOMA; CLEAR CELL CARCINOMA; CYTOLOGY; CYTOPLASM; DIFFERENTIAL DIAGNOSIS; DISEASE SPECIFIC SURVIVAL; DNA METHYLATION; DNA REPAIR; DOWN REGULATION; EPIGENETICS; FAMILIAL CANCER; FOLLOW UP; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETICS; HETEROZYGOSITY; HIGH GRADE SEROUS CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LOW GRADE SEROUS CARCINOMA; NEPHROBLASTOMA; OVARIAN SEROUS CARCINOMA; OVARY; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; OVULATION; PERITONEUM; PERITONEUM CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SALPINGOOOPHORECTOMY; SECRETORY CELL OUTGROWTH; SEROUS TUBAL INTRAEPITHELIAL CARCINOMA; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; UTERINE TUBE;

CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 84865381589     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04167.x     Document Type: Review

References (81)

1. Jamal A, Siegel R, Ward E et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010; 60; 277-300.
2. Seidman JD, Horkayne-Szakaly I, Haiba M et al. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int. J. Gynecol. Pathol. 2004; 1; 41-44.
3. Malpica A, Deavers M, Lu K et al. Grading ovarian serous carcinoma using a two-tier system. Am. J. Surg. Pathol. 2004; 28; 496-504.
4. Malpica A, Deavers M, Tornos C et al. Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma. Am. J. Surg. Pathol. 2007; 31; 1168-1174.
5. Singer G, Oldt R, Cohen Y et al. Mutations in BRAF and DRAS characterize the development of low-grade ovarian serous carcinoma. J. Natl Cancer Inst. 2003; 22; 37-41.
6. Singer G, Kurman R, Chang H et al. Diverse tumorigenic pathways in ovarian serous carcinoma. Am. J. Pathol. 2002; 4; 1223-1228.
7. Singer G, Stohr R, Cope L. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis. A mutational analysis with immunohistochemical correlation. Am. J. Surg. Pathol. 2005; 29; 218-224.
8. Salani R, Kurman R, Giuntoli R. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int. J. Gynecol. Cancer 2008; 18; 487-491.
9. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474; 609-615.
10. Kuo KT, Guan B, Feng Y et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer Res. 2009; 9; 4036-4042.
11. Ayhan A, Kurman R, Yemelyanova A et al. Defining the cut point between low-grade and high-grade ovarian serous carcinomas. A clinicopathologic and molecular genetic analysis. Am. J. Surg. Pathol. 2009; 33; 1220-1224.
12. Vang R, Shih I, Salani R et al. Subdividing ovarian and peritoneal serous carcinoma into moderately differentiated and poorly differentiated does not have biologic validity based on molecular genetic and in vitro drug resistance data. Am. J. Surg. Pathol. 2008; 32; 1667-1674.
13. Risch H, McLaughlin J, Cole D et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 2001; 68; 700-710.
14. Pal T, Permuth-Wey J, Betts J et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005; 12; 2807-2816.
15. King M, Marks J, Mandell J et al. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003; 302; 643-646.
16. Rebbeck T, Lynch H, Neuhausen S et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 2002; 346; 1616-1622.
17. Kauff N, Satagopan J, Robson M et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N. Engl. J. Med. 2002; 23; 1609-1615.
18. Finch A, Shaw P, Rosen B et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol. Oncol. 2006; 100; 58-64.
19. Colgan T, Murphy J, Cole D et al. Occult carcinoma in prophylactic oophorectomy specimens. Prevalence and association with BRCA germline mutation status. Am. J. Surg. Pathol. 2001; 25; 1283-1289.
20. Powell C, Kenley E, Chen L et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J. Clin. Oncol. 2005; 23; 127-132.
21. Medeiros F, Muto M, Yonghee L et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 2006; 30; 230-236.
22. Callahan M, Crum C, Medeiros F et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J. Clin. Oncol. 2007; 25; 3985-3990.
23. Leeper K, Garcia R, Swisher E et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol. Oncol. 2002; 98; 52-56.
24. Lee Y, Medeiros F, Kindelberger D et al. Advances in the recognition of tubal intraepithelial carcinoma. Applications to cancer screening and the pathogenesis of ovarian cancer. Adv. Anat. Pathol. 2006; 13; 1-7.
25. Press J, DeLuca A, Boyd N et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008; 8; 17.
26. Kindelberger D, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am. J. Surg. Pathol. 2007; 31; 161-169.
27. Przybycin C, Kurman R, Ronnett B et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am. J. Surg. Pathol. 2010; 34; 1407-1416.
28. Chen E, Mehra K, Mehrad M et al. Secretory cell outgrowth, PAX2, and serous carcinogenesis in the fallopian tube. J. Pathol. 2010; 222; 110-116.
29. Roh M, Yassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN, and PAX2 expression. Mod. Pathol. 2010; 23; 1316-1324.
30. Lee Y, Miron A, Drapkin R et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J. Pathol. 2007; 211; 26-35.
31. Folkins A, Jarboe E, Saleemuddin A et al. A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol. Oncol. 2008; 109; 168-173.
32. Shaw P, Rouzbahman M, Pizer E et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA 1/2 mutation carriers. Mod. Pathol. 2009; 22; 1133-1138.
33. Mehra K, Chang M, Folkins A et al. The impact of tissue block sampling on the detection of p53 signatures in fallopian tubes from women with BRCA 1 or 2 mutations (BRCA+) and controls. Mod. Pathol. 2010; 1; 1-5.
34. Jarboe E, Folkins A, Nucci M et al. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int. J. Gynecol. Pathol. 2007; 27; 1-9.
35. Carlson J, Jarboe E, Kindelberger D et al. Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications. Int. J. Gynecol. Pathol. 2010; 29; 310-314.
36. Visvanathan K, Vang R, Shaw P et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am. J. Surg. Pathol. 2011; 35; 1766-1775.
37. Bowen N, Logani S, Dickerson E et al. Emerging roles for PAX8 in ovarian cancer and endosalpingeal development. Gynecol. Oncol. 2007; 104; 331-337.
38. Hibbs K, Skubitz K, Pambuccian S et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am. J. Pathol. 2004; 165; 397-414.
39. Marquez R, Baggerly K, Patterson A et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 2005; 11; 6116-6126.
40. Kurman R, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am. J. Surg. Pathol. 2010; 34; 433-443.
41. Seidman J, Zhao P, Yemelyanova A. 'Primary peritoneal' high-grade carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancer. Gynecol. Oncol. 2011; 120; 470-473.
42. Carlson J, Miron A, Jarboe E et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J. Clin. Oncol. 2008; 26; 4160-4165.
43. Gu J, Roth L, Younger C et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J. Natl Cancer Inst. 2001; 93; 1147-1152.
44. Lu D, Bell D, Welch W et al. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res. 1998; 58; 2328-2330.
45. Sieben N, Kolkman-Uljee S, Flanagan A et al. Molecular genetic evidence for monoclonal origin of bilateral ovarian serous borderline tumors. Am. J. Pathol. 2003; 162; 1095-1101.
46. Sieben N, Roemen G, Oosting J et al. Clonal analysis favours a monoclonal origin for serous borderline tumours with peritoneal implants. J. Pathol. 2006; 210; 405-411.
47. Krishnamurti U, Sasatomi E, Swalsky P. Microdissection-based mutational genotyping of serous borderline tumors of the ovary. Int. J. Gynecol. Pathol. 2004; 24; 56-61.
48. Kurman RJ, Vang R, Junge J et al. Papillary Tubal Hyperplasia: The Putative precursor of ovarian atypical proliferative (borderline) serous tumors, noninvasive implants, and endosalpingiosis. Am. J. Surg. Pathol. 2011; 35; 1605-1614.
49. Laury AR, Ning G, Quick CM et al. Fallopian Tube correlates of ovarian serous borderline tumors. Am. J. Surg. Pathol. 2011; 35; 1759-1765.
50. Che M, Tornos C, Deavers M et al. Ovarian mixed-epithelial carcinomas with a microcystic pattern and signet-ring cells. Int. J. Gynecol. Pathol. 2001; 20; 323-328.
51. Soslow R, Han G, Olvera N et al. Morphologic patterns associated with BRCA1 and BRCA2 genotype. Mod. Pathol. 2011; 1(Suppl.); 266A (abstract 1132).
52. Fujiwara M, Felberg A, Whittemore A et al. Germline BRCA1 mutation positive ovarian cancer exhibits a distinctive highly specific phenotype. Mod. Pathol. 2011; 1(Suppl.); 246A (abstract 1043).
53. Acs G, Pasha T, Zhang M et al. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int. J. Gynecol. Pathol. 2004; 23; 110-118.
54. Han G, Gilks B, Leung S et al. Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma. An interobserver correlative and immunohistochemical study of 32 cases. Am. J. Surg. Pathol. 2008; 32; 955-964.
55. Kobel M, Kalloger S, Carrick J et al. A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. Am. J. Surg. Pathol. 2009; 33; 14-21.
56. McKenney J, Balzer B, Longacre T et al. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion. Am. J. Surg. Pathol. 2006; 30; 1209-1221.
57. Gershenson D, Sun C, Lu K et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet. Gynecol. 2006; 108; 361-368.
58. Kobel M, Kalloger S, Huntsman D et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int. J. Gynecol. Pathol. 2010; 29; 203-211.
59. Sehdev A, Sehdev P, Kurman R et al. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary. A clinicopathologic analysis of 135 cases. Am. J. Surg. Pathol. 2003; 27; 725-736.
60. Ali R, Kalloger S, Santos J et al. Stage II-IV low grade serous carcinoma of the ovary: a clinicopathological study of 33 patients. Mod. Pathol. 2011; 1(Suppl.); 234A (abstract 991).
61. Thigpen T, Brady MF, Omura GA et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 1993; 71; 606-614.
62. Bristow R, Tomacruz R, Armstrong D et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 2002; 20; 1248-1259.
63. Omura GA, Brady MF, Homesley HD et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynecologic Oncology Group experience. J. Clin. Oncol. 1991; 7; 1138-1150.
64. Chi DS, Eisenhauer EL, Lang J et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)? Gynecol. Oncol. 2006; 103; 559-564.
65. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J. Clin. Oncol. 1991; 9; 139-383.
66. Bolis G, Parazzini F, Scardone G et al. Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer. Gynecol. Oncol. 1999; 72; 60-64.
67. Zorn K, Tian C, McGuire W et al. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study. Cancer 2009; 115; 1028-1035.
68. Bakkar R, Gershenson D, Silva E et al. Stage IIIC ovarian cancer: a heterogeneous group of patients with different prognosis. Mod. Pathol. 2011; 1(Suppl.); 236A (abstract 1000).
69. Patel D, Silva E, Walsh C et al. The significane of the pattern of invasion in high grade serous carcinoma of the ovary. Mod. Pathol. 2011; 1(Suppl.); 262A (abstract 1114).
70. Chetrit A, Hirsh-Yechezkel G, Yehuda B et al. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J. Clin. Oncol. 2008; 26; 20-25.
71. Boyd J, Sonoda Y, Federici M et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283; 2260-2265.
72. Tan D, Rothermundt C, Thomas K et al. 'BRCAness' syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J. Clin. Oncol. 2008; 26; 5530-5536.
73. Zhang L, Conejo-Garcia J, Katsaros D et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003; 348; 203-213.
74. Clarke B, Tinker A, Cheng-Han L et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 2009; 22; 393-402.
75. Farmer H, McCabe N, Lord C et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434; 917-921.
76. Fong P, Boss D, Yap T et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 2009; 261; 123-134.
77. Konstantinopoulos P, Spentzos D, Karlan B et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 2010; 28; 3555-3561.
78. Schmeler K, Sun C, Bodurka D et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol. Oncol. 2008; 108; 510-514.
79. Gershenson D, Sun C, Bodurka D et al. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol. Oncol. 2009; 114; 48-52.
80. Sebolt-Leopold J, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 2004; 4; 937-947.
81. Sebolt-Leopold J. Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin. Cancer Res. 2008; 12; 3651-3656.